Reuters logo
BRIEF-Novo Nordisk launches Tresiba in the United States
January 26, 2016 / 1:08 PM / 2 years ago

BRIEF-Novo Nordisk launches Tresiba in the United States

Jan 26 (Reuters) - Novo Nordisk A/S

* Novo Nordisk launches Tresiba in the United States

* Long-acting Tresiba U-200 now available for adults living with diabetes

* Tresiba (insulin degludec injection) is a once-daily, long-acting basal insulin

* Tresiba was approved by the U.S. Food and Drug Administration (FDA) in September 2015

* Novo Nordisk is working to secure coverage for Tresiba on U.S. health plans and has secured Lowest Brand Co-pay status on the national formulary for CVS Caremark Further company coverage: (Reporting By Sabina Zawadzki, editing by Teis Jensen)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below